Q-omics provides the consensus-scored TRIM45 profile across patient tissues and cancer cell-line models. TRIM45 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TRIM45 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TRIM45 RNA expression shows 19,754 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, KIRC, and UVM as cancer lineages where TRIM45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM45 survival associations across molecular data types. TRIM45 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM45 RNA expression–survival associations across cancer types. High TRIM45 expression shows unfavorable associations in ACC, THCA, DLBC, LIHC and KICH, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TRIM45 RNA expression.
This table summarizes TRIM45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRIM45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM45 shows lower tumor expression in KIRC, THCA and KICH and higher tumor expression in LIHC, BLCA and LUAD. The KIRC box plot shows higher TRIM45 RNA expression in normal versus tumor tissue (log2 FC = −0.675, t-test p < 0.001).
This table shows molecular features associated with TRIM45 in patient tissues and cancer cell lines. In patient samples, TRIM45 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRIM45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
